(Q33344308)

26 July 2017

title

Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

Nobuyuki Naka

1

1 reference

26 July 2017

Masaaki Kawahara

2

1 reference

26 July 2017

Kyoichi Okishio

3

1 reference

26 July 2017

Shigeto Hosoe

4

1 reference

26 July 2017

Mitsumasa Ogawara

5

1 reference

26 July 2017

Shinji Atagi

6

1 reference

26 July 2017

Yuuji Takemoto

7

1 reference

26 July 2017

Kiyonobu Ueno

8

1 reference

26 July 2017

Tomoya Kawaguchi

9

1 reference

26 July 2017

Tessei Tsuchiyama

10

1 reference

26 July 2017

Kiyoyuki Furuse

11

1 reference

26 July 2017

publication date

1 September 2002

1 reference

26 July 2017

1 reference

26 July 2017

volume

37

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

319-323

1 reference

Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

Second-line chemotherapy for relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900073-9

7 January 2021

10.1016/S0169-5002(02)00073-9

Identifiers

DOI

1 reference

26 July 2017

1 reference